U. Minn team

University of Minnesota is one of twenty-two type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Antoinette Moran, MD, the TrialNet team at University of Minnesota is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis. 

Our Team

Portrait photo

Antoinette Moran, MD

Portrait photo

Brandon Nathan, MD

Portrait photo

Muna Sunni, MD

shannon beasley

Shannon Beasley, NP

Portrait photo

Beth Pappenfus

Jane Kennedy


Janice Leschyshyn, RN

Ihsan RIzky

Regional Affiliates

Central Iowa Hospital Corporation
1215 Pleasant St., Ste 300 , Des Moines, 50309 United States
University of Iowa, Childrens Hospital of Iowa
25 S Grand Avenue 2160 ML , Iowa City, 52242 United States
Sanford Children's Specialty Clinic
1018 West 18th Street , Sioux Falls, 57104 United States
Sanford Research - Fargo
737 Broadway N , Fargo, 58122 United States

Research Studies

Risk Screening Risk Screening for Relatives

If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More

Monitoring Monitoring

Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More

Prevention Study Abatacept Prevention Study

TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 or stage 2), and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression. Details

Prevention Study Hydroxychloroquine (HCQ)

We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D. Details

Long Term Long-Term Follow-up

If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More

Newly Diagnosed Tolerance Using Plasmid (TOPPLE) Study: Phase 1

TrialNet is testing the safety of a new treatment, NNC0361-0041, in adults diagnosed with type 1 diabetes (T1D) in the past 48 months. This is a Phase 1 study, which means it is the first time this treatment is being tested for safety in people. If this study results in no safety concerns, we plan to conduct a larger study to see if this same treatment can slow down or stop T1D in people at high risk, before clinical diagnosis. More

#T1DFamily Spotlight

Meet some of our TrialNet #T1DFamily members to learn what it’s like to participate in a TrialNet clinical research study.